Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Exec Compensation
confidence 92%
filed 2026-07-28
The Board approved adoption of a restricted stock award (RSA) program under the 2025 Equity Incentive Plan on July 25, 2026, reserving 1,340,000 ordinary shares (approximately 3% of outstanding shares) for grant and settlement of RSAs with three-year vesting tied to continued service. This is a compensatory arrangement for directors and officers that materially affects equity structure and would be disclosed under Item 5.02(e) equivalent in a domestic 8-K.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 85%
filed 2026-07-28
The 6-K discloses amendment of the 2022 Incentive Equity Plan to increase authorized shares and grants of 100,000 restricted stock units to CEO Haggai Alon and 10,000 RSUs to a consultant, with all RSUs vesting upon grant. This is a compensatory arrangement for a named executive officer (the CEO), fitting the exec_compensation category. The lock-up restriction (no trading before January 22, 2027) and the material size of the CEO grant (100,000 RSUs) make this material to investors assessing executive compensation practices.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-28
The filing discloses Item 5.02(e) compensation arrangements: the Compensation Committee approved amendments to accelerate vesting of restricted stock awards granted on June 24, 2026, with full vesting on July 27, 2026. Named executives (CEO Ezra Beyman, CFO Joel Markovits, COO Judah Korman, and others) and directors received accelerated equity awards totaling thousands of shares. This is a material compensatory arrangement modification affecting executive and director equity holdings.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-28
Item 5.02
The filing discloses compensatory arrangements approved by the Compensation Committee on July 24, 2026, including a warrant grant to CEO Dr. Allan Evans (5,000,000 shares at $25.00 exercise price, vesting upon stock price targets) and stock option grants to three executive officers (Andrew Camden, Brian Hoff, and Stacy Wright). The CEO's arrangement is particularly material as it involves a substantial equity grant coupled with a waiver of all cash compensation following December 31, 2026. This is a classic Item 5.02(e) disclosure of executive compensation arrangements.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 72%
filed 2026-07-27
Item 7.01
The filing discloses Board approval of equity grants totaling 400,000 stock options and 2,490,000 RSUs to directors, officers, and employees under the Company's equity incentive plan. While the press release also announces the timing of Q2 2026 earnings release and conference call (a routine disclosure), the substantive material event disclosed is the compensatory arrangement—the grant of equity awards with specified exercise prices, vesting schedules, and beneficiary classes. This falls squarely within exec_compensation as a disclosure of equity grants to named executive officers and directors.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-07-27
Item 5.02
The compensation committee approved an amendment to the 2025 Inducement Equity Incentive Plan, increasing the share reserve from 2,000,000 to 2,625,967 shares to support equity awards for new employees and non-employee directors.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-27
Item 5.02
The disclosure centers on amendment of Mark R. McCollom's employment agreement as Executive Vice President and Chief Financial Officer. While the amendment modifies several terms (auto-renewal, notice periods, release requirement, insurance continuation, and non-compete covenant), the core event is a compensatory arrangement modification affecting a named executive officer. The changes to severance conditions, benefits continuation, and restrictive covenants are material terms of his compensation package, making this an exec_compensation event rather than a departure or appointment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The disclosure centers on compensatory arrangements for Adam B. Sefchick, the Company's CFO and Interim CEO. The Compensation Committee approved multiple compensation elements: increased base salary ($290,000 to $302,000), increased bonus target ($60,000 to $70,000), a restricted stock grant of 20,222 shares valued at $100,000, additional monthly compensation of $10,000 for interim CEO duties, discretionary bonuses, and new severance and change-in-control agreements. This is a comprehensive executive compensation arrangement disclosure, material to investors assessing executive pay and retention incentives.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-07-24
Item 5.02
Stockholders approved and adopted an amended and restated Long-Term Stock Incentive Plan effective July 22, 2026, establishing a 6,000,000 share reserve, extending the plan term through 2036, and modifying compensation provisions including director compensation limits and equity award settlement mechanics.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The Compensation Committee approved special one-time equity awards (Sustainment Awards) totaling $25 million in aggregate to three named executives (Kenneth Sharp, Kenneth Bedingfield, and Samir Mehta), consisting of 50% PSUs and 50% RSUs with performance conditions and three-year vesting. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure, and material given the substantial grant values and performance-based structure tied to shareholder interests.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The Board and Compensation Committee approved grants of performance share units (PSUs) totaling 500,000 units at target to three named executives (CEO Harold Bevis, COO Tim French, and CFO Chris Bohnert) on July 23, 2026. The disclosure details the vesting conditions tied to performance metrics (adjusted EBITDA, free cash flow, net sales, and TSR) and change-of-control provisions, which are classic compensatory arrangements. This is a material equity grant to senior leadership designed to reward performance, motivate strategy achievement, and retain executives.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The disclosure centers on the Human Capital and Compensation Committee's approval of a long-term performance-based restricted stock grant of 161,500 shares (approximately $15 million grant date fair value) to John M. Holmes, the CEO and President. This is a compensatory arrangement for a named executive officer, specifically a performance-based equity grant with five-year vesting tied to stock price hurdles. The event is material as it represents a significant executive compensation decision affecting the CEO's incentive structure and long-term retention.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-24
Item 5.02
The filing discloses two compensatory arrangements: (1) approval of a new Executive Severance Plan governing future executive officer separations with specified multipliers and benefits, replacing prior Management Retention Agreements, and (2) establishment of a one-time special bonus pool for approximately 1,100 managing directors and above, with named executive officers receiving $1.9M and $850K respectively. Both are material executive compensation matters disclosed under Item 5.02(e).
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The Compensation Committee approved special grants of performance-based restricted stock units (PSUs) to Ronald F. Clarke and Armando L. Netto on July 22, 2026. The disclosure details the grant amounts (300,000 and 28,213 PSUs respectively), performance conditions tied to stock price hurdles ($425, $450, and $475), and the vesting period through August 31, 2028. This is a compensatory arrangement for named executives intended to align their interests with shareholder value and retain their services, fitting squarely within the exec_compensation category.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The filing discloses an amendment to CEO Daniel H. Schulman's employment agreement that modifies his compensation arrangements, including extension of his employment term through December 31, 2028, specification of base salary and incentive targets for 2028, and a long-term incentive award with a target value of at least $25 million. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The disclosure centers on compensatory arrangements for the CEO, Lou Torchio, specifically the approval and grant of restricted stock units totaling approximately $2,000,000 (Original Award) and a subsequent New Award of 125,298 RSUs approved on July 22, 2026. The filing details vesting schedules, acceleration provisions, and settlement terms—all hallmarks of executive compensation disclosure under Item 5.02(e). While the section header mentions departures and appointments, the substantive content is exclusively about compensation arrangements.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
The filing discloses Item 5.02(e) compensatory arrangements for John Belizaire, the CEO. The Committee approved an increase in his annual base salary to $600,000 (retroactive to January 1, 2026) and established a target annual bonus opportunity of 100% of base salary tied to performance goals. This is a material executive compensation change affecting a named executive officer.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The disclosure centers on severance and compensatory arrangements entered into on July 24, 2026 with two named executives (Martin Layding, COO/CFO, and Melinda Paraie, Chief Brand Officer). The filing details specific severance benefits including base salary continuation, bonus payments, equity vesting acceleration, and change-of-control protections—all hallmarks of executive compensation arrangements under Item 5.02(e). While severance can signal potential departures, the prose focuses on the *terms and conditions* of the compensation arrangement itself, not on an actual termination event.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The disclosure centers on compensatory arrangements for two named executives: issuance of 35,240 RSUs and 11,530 PBRSUs to Reagan Tuck Dukes (COO) and Robert J. Long (CFO) on July 21, 2026, along with new Employment Agreements entered into on July 21-22, 2026 specifying base salaries ($300,000 and $280,000 respectively), targeted bonuses (50% of salary), severance provisions, and equity eligibility. This is a classic Item 5.02(e) disclosure of compensatory arrangements, distinct from an appointment or departure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The Board adopted an Amended and Restated Executive Severance Plan on July 23, 2026, modifying severance arrangements for executive officers. The disclosure details material changes to compensatory arrangements including updated severance multiples (from salary continuation to two times base salary plus target bonus in change-of-control scenarios), new severance for non-change-of-control terminations, and a Section 280G cut-back provision. This is a plan amendment affecting executive compensation and severance terms, fitting squarely within exec_compensation rather than exec_departure or exec_appointment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-23
Item 5.02
This Item 5.02(e) disclosure details special one-time equity awards (PSUs and RSUs valued at approximately $15 million each) and carried interest allocations granted to the CEO, Executive Chairman, and three Co-Presidents effective July 21, 2026. The disclosure explicitly addresses compensatory arrangements—equity grants and performance-based incentives—approved by the Compensation Committee and Board to retain core leadership and align compensation with company performance, which is the hallmark of exec_compensation classification.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-23
The 6-K discloses adoption of the 2026 Second Equity Incentive Plan and grants of 400,000 restricted shares to employees, including 200,000 Class B shares to CEO and Chairman Siping Xu. This is a compensatory arrangement involving equity grants to named executives, which is the core substance of exec_compensation. The grant to Xu is material as it increases his voting control to 89.71% of outstanding shares.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-23
Item 5.02
The disclosure centers on the Compensation Committee's approval of stock option grants (100,000 options to CEO Robert C. Jahr and 210,078 options to CFO Lawrence A. Kenyon) and cash bonus opportunities ($420,000 and $200,000 respectively) contingent on FDA approval of ONS-5010. This is a classic compensatory arrangement disclosure under Item 5.02(e), involving equity grants and performance-based cash awards to named executives.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-23
Item 5.02
The Board approved one-time supplemental performance-based stock option grants to current employees including CEO Anand Parikh (398,018 options), General Counsel Christopher Gerry (84,766 options), and SVP Finance Josiah Craver (30,824 options) under the 2026 Equity Incentive Plan. This is a compensatory arrangement for named executives and officers, with vesting contingent on achieving a $70.00 stock price hurdle over a four-year performance period. The disclosure of equity grants to senior management constitutes a material executive compensation event.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-23
Item 5.02
The disclosure centers on compensatory arrangements for Robert Rasmus, the President, CEO, and director. The Amendment modifies his salary to $50,000, eliminates bonus and long-term incentive eligibility, and authorizes grants of 600,000 time-based RSUs and 600,000 performance-based RSUs under the 2026 Omnibus Incentive Plan, plus an extension of 400,000 inducement RSUs. These are material equity and cash compensation modifications that would affect investor assessment of executive pay and incentive alignment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-23
Item 5.02
The Committee approved the Company Short-Term Incentive Plan (STIP) effective January 1, 2026, and established fiscal year 2026 target opportunities for the principal executive officer (Scott Griffith), principal financial officer (Jody Davis), and other named executive officers. The disclosure details the performance metrics (adjusted EBITDA and revenue at 50% each), target payouts (50% of base salary for each officer), and payout ranges (0% to 150% of target), which constitutes a material compensatory arrangement for named executives.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-23
Item 5.02
The Compensation Committee approved one-time equity awards (125,000 RSUs to CEO Kovler, 50,000 RSUs to President Irwin, and 35,000 RSUs to CFO Mulvihill) granted on July 20, 2026 in recognition of the executives' contributions to the Company's strategic transformation and entry into definitive agreements for approximately $39.4 million in strategic investment. This is a compensatory arrangement for named executives disclosed under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-23
Item 5.02
The disclosure centers on an Amended and Restated Employment Agreement with CEO Steve Ledger that modifies his compensatory arrangements, including base salary ($500,000), target bonus (50% of base), equity awards, and severance/change-of-control provisions. While the agreement amends an existing employment contract, the principal disclosed action is the modification of executive compensation terms, severance multiples, and equity vesting provisions—all hallmarks of exec_compensation rather than appointment or departure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-22
Item 5.02
The disclosure centers on the Compensation Committee's recommendation and Board adoption of a 2026 Performance Stock Unit Program for senior executive officers, including the establishment of PSU awards with specific vesting conditions, settlement terms, and change-of-control provisions. This is a compensatory arrangement for named executives under Item 5.02(e), distinct from an appointment or departure. The materiality is clear given the program's scope, the market-vesting conditions tied to stock price thresholds, and the three-year settlement timeline affecting executive incentive compensation.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-22
The disclosure reports issuance of 2.5 million Class A and 200,000 Class B ordinary shares to More Healthy Holdings Limited (the holding vehicle of Mr. Weiguang Yang, the CEO and Chairman) on July 21, 2026, "in consideration and acknowledgement of Mr. Weiguang Yang's services rendered to the Company." This is an equity grant to a named executive officer approved by the Audit Committee and Compensation Committee, fitting the definition of executive compensation. The transaction is material because it results in Mr. Yang holding 99.45% of aggregate voting power and represents a substantial equity award to the controlling executive.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-22
EX-99.1
The disclosure announces approval by the Nomination, Governance and Compensation Committee of a grant of 15,933 stock options to eligible employees under the Dr. Reddy's Employees Stock Option Scheme, 2018, with an exercise price of Rs. 1,206 per share and 100% vesting over 3 years. This is a compensatory arrangement for employees and falls squarely within exec_compensation. The filing is made under SEBI Regulation 30 and includes detailed terms required by the SEBI Master Circular, indicating material disclosure of equity-based compensation.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-21
Item 5.02
The disclosure centers on Board approval of a one-time discretionary cash award of $100,000 to Marcus Laun, the President and interim CEO/CFO, in recognition of his service and leadership. This is a compensatory arrangement for a named executive officer approved outside the regular incentive program, fitting the definition of exec_compensation under Item 5.02(e). The award is material as it represents a significant discretionary payment to a senior executive.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-21
Item 5.02
First Amendment to the Executive Employment Agreement for President and CEO Tamria Zertuche extends her employment term through July 31, 2029 and establishes a new annual base salary of $935,000 effective August 1, 2026, along with eligibility for incentive plans and severance benefits.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 85%
filed 2026-07-21
The Board approved an increase in ordinary shares reserved for issuance under the Company's Amended and Restated 2019 Equity Incentive Plan by 3,834,244 shares (from 11,875,977 to 15,710,221). This is a material amendment to the equity compensation plan that expands the pool available for executive and employee equity grants, directly affecting the compensatory arrangements available to named executives and other employees.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 88%
filed 2026-07-21
Item 5.02
Mitesco issued Series X Preferred Stock and restricted common stock as compensatory arrangements to executives and directors: 4,800 shares ($120,000) to the CEO, 2,400 shares ($60,000) to each of two directors, and 2,400 shares ($60,000) to an acquisition advisor. The issuances materially affect the company's capital structure and governance, with preferred shareholders obtaining over 59% voting control and a cumulative 10% dividend obligation.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-21
Item 5.02
Shareholders approved the Radnostix Inc. 2026 Incentive Plan, a new equity incentive plan authorizing 12,000,000 shares for awards to employees, officers, directors, and service providers. The plan replaces the prior equity plan and establishes material terms for executive and director compensation eligibility.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-21
Item 5.02
The company entered into Executive Employment Agreements effective July 17, 2026, with CEO Ricardo Enrique Silva Canelon and COO Andrew Gaudet, establishing equity-based compensation arrangements whereby Canelon receives 36 million restricted shares and Gaudet receives 12 million restricted shares, both fully vested upon board approval and execution.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-21
The filing discloses two compensatory arrangements for officers and employees under Item 5.02: (1) a board determination regarding acceleration of approximately 1.6 million PSU awards in connection with the Merger Transactions closing on July 13, 2026, and (2) a grant of 360,000 restricted stock awards to officers and employees on July 15, 2026 under the 2023 Amended and Restated Omnibus Incentive Plan. Both are equity compensation arrangements materially affecting executive and employee incentive structures.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-20
Item 5.02
The filing discloses adoption of the 2026 Short-Term Incentive Plan establishing annual cash incentive compensation for named executive officers with specific performance goals and payout schedules, and an amended employment agreement reducing CEO Todd Brickhouse's base salary to $1,750,000 effective July 25, 2026. These are compensatory arrangements for officers that would materially affect investor assessment of executive compensation structure and CEO pay.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-20
Item 5.02
The company granted RSUs and PSUs to CEO Asim Akram and CFO Robert Nadolny, and amended their RSU Award Agreements and employment agreements to modify change-of-control vesting provisions and establish new equity award treatment in M&A scenarios.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 75%
filed 2026-07-20
EX-99.1
Founder and CEO Dr. Silviu Itescu exercised 1,885,334 options at A$1.45 per share, investing A$2,733,734 to increase his shareholding to 80,844,262 shares, reflecting the exercise of compensatory equity arrangements.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-20
Item 5.02
The Board adopted a new Short-Term Incentive Cash Compensation Plan and amended and restated the Long-Term Cash Incentive Plan, both effective July 14, 2026, governing annual cash incentive awards and long-term compensation for named executive officers. The Long-Term Plan amendment materially expands vesting rights by allowing all unvested awards to vest upon retirement at age 65 with three years of service, regardless of grant date—a significant change from the prior requirement that awards be granted at least three years before retirement. These are compensatory arrangements for officers subject to Section 16 disclosure under Item 5.02(e).
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-17
Sony announced the disposal of 1,142,196 treasury shares upon vesting of restricted stock units (RSUs) granted to directors, officers, and employees under its stock compensation plan. The announcement details the vesting mechanics, allottees (including 1 director and 1 corporate executive officer of the Corporation), and the total disposal price of approximately 3.9 billion yen. This is a material disclosure of compensatory arrangements involving equity grants and their settlement, falling squarely within exec_compensation rather than a routine administrative matter.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-07-17
EX-99.1
This announcement discloses the grant of 16,220,972 restricted share units (RSUs) to 438 employees under the 2026 Share Incentive Plan on July 17, 2026, representing approximately 0.36% of total issued shares. The disclosure details vesting schedules, performance conditions, clawback mechanisms, and the rationale for the grants—all hallmarks of executive and employee compensation arrangements. While the grantees are not named executives, the scale and structure of this equity grant constitute a material compensatory arrangement requiring disclosure under Hong Kong Listing Rules 17.06A–C.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-17
EX-99.1
This exhibit is the 2026 Omnibus Share Incentive Plan adopted by the Board on July 13, 2026. It establishes a comprehensive equity compensation framework authorizing grants of options, restricted shares, share units, and cash-based awards to employees, consultants, and directors. The plan document itself—setting forth the terms, conditions, and administration of compensatory arrangements—constitutes a material disclosure of executive and employee compensation arrangements under Item 5.02(e) equivalent disclosure obligations for foreign private issuers.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-17
Item 5.02
The Board approved a comprehensive executive compensation program for fiscal 2027 covering four named executive officers (Covered NEOs), including detailed annual incentive targets (50–150% of base salary based on operating income and revenue metrics) and long-term incentive awards (65% RSUs, 35% PSUs with three-year performance periods). This is a material compensatory arrangement disclosure under Item 5.02(e), distinct from any executive departure or appointment.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-17
The disclosure announces the formal implementation of previously approved share option arrangements for directors and the CEO. Specifically, it grants 400,000 options to Non-Executive Director Mark Thorpe (at £2.55 exercise price), 100,000 options to Non-Executive Director Michael Schlumpberger (at £1.31), and grants a new EMI option of 181,817 shares to CEO Oliver Friesen (at 10.75p) while extending his original option by five years and providing tax indemnification. These are compensatory arrangements for named executives that would materially affect investor assessment of executive remuneration and equity dilution.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-16
Item 5.02
The disclosure centers on compensatory arrangements granted to two named executives: stock options to purchase 2,700,000 shares for CEO Gerald Bartholomew Smith and 1,100,000 shares for COO Laine Mihalchick Moljo under the 2026 Omnibus Incentive Plan, with detailed vesting terms and change-of-control provisions. This is a classic equity grant arrangement under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-16
Item 5.02
The Board approved one-time lump sum cash bonuses for CEO Lindsay Androski and CFO Tuan Nguyen tied to litigation settlement proceeds, with Androski receiving 1.5% of noncontingent payments ($178M), 2.0% of contingent proceeds, and 2.5% of Pfizer/BioNTech litigation proceeds, and Nguyen receiving 0.25% of noncontingent proceeds and potential future bonuses.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-16
Item 5.02
Shareholders approved an amendment to the 2018 Equity Incentive Plan increasing the share pool by 2,500,000 ordinary shares, expanding the equity available for compensatory grants to officers and directors.
View raw filing on EDGAR →